HnRNP A1/A2 and SF2/ASF Regulate Alternative Splicing of Interferon Regulatory Factor-3 and Affect Immunomodulatory Functions in Human Non-Small Cell Lung Cancer Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Guo, Rong ^a   Li, Yong ^b   Ning, Jinying ^c   Sun, Dan ^a   Lin, Lianjun ^a   Liu, Xinmin ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c Crown Bioscience Inc (Beijing)   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE SPLICING FACTOR; BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 10; MESSENGER RNA; PHYTOHEMAGGLUTININ; SMALL INTERFERING RNA; SPLICING FACTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CANCER CELL; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; GEL MOBILITY SHIFT ASSAY; GENE CONSTRUCT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTRON; LUNG NON SMALL CELL CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION; WESTERN BLOTTING;

ALTERNATIVE SPLICING; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOKINE CXCL10; COCULTURE TECHNIQUES; EXONS; GENE EXPRESSION REGULATION; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; IMMUNOMODULATION; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; INTRONS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; RNA PRECURSORS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84876929370     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062729     Document Type: Article

References (59)

1. Cáceres JF, Kornblihtt AR, (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18: 186-193.
2. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ, (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40: 1413-1415.
3. Colobran R, Pujol-Borrell R, Armengol MP, Juan M, (2007) The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility. Clin Exp Immunol 150: 1-12.
4. Tauler J, Mulshine JL, (2009) Lung cancer and inflammation: interaction of chemokines and hnRNPs. Curr Opin Pharmacol 9: 384-388.
5. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J, (2011) The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 90: 484-494.
6. Venables JP, (2006) Unbalanced alternative splicing and its significance in cancer. Bioessays 28: 378-386.
7. David CJ, Chen M, Assanah M, Canoll P, Manley JL, (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-368.
8. Liu Y, Wu BQ, Zhong HH, Tian XX, Fang WG, (2012) Quantification of alternative splicing variants of human telomerase reverse transcriptase and correlations with telomerase activity in lung cancer. PLoS One 7: e38868.
9. He Y, Smith R, (2009) Nuclear functions of heterogeneous nuclear ribonucleoproteins A/B. Cell Mol Life Sci 66: 1239-1256.
10. He Y, Brown MA, Rothnagel JA, Saunders NA, Smith R, (2005) Roles of heterogeneous nuclear ribonucleoproteins A and B in cell proliferation. J Cell Sci 118: 3173-3183.
11. Cui H, Wu F, Sun Y, Fan G, Wang Q, (2010) Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma. BMC Cancer 10: 356.
12. Pino I, Pío R, Toledo G, Zabalegui N, Vicent S, et al. (2003) Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 41: 131-143.
13. Zhou J, Allred DC, Avis I, Martínez A, Vos MD, et al. (2001) Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res Treat 66: 217-224.
14. Zhao W, Wang L, Zhang M, Wang P, Qi J, et al. (2012) Nuclear to cytoplasmic translocation of heterogeneous nuclear ribonucleoprotein U enhances TLR-induced proinflammatory cytokine production by stabilizing mRNAs in macrophages. J Immunol 188: 3179-3187.
15. Long JC, Caceres JF, (2009) The SR protein family of splicing factors: master regulators of gene expression. Biochem J 417: 15-27.
16. Buratti E, Stuani C, De Prato G, Baralle FE, (2007) SR protein mediated inhibition of CFTR exon 9 inclusion: molecular characterization of the intronic splicing silencer. Nucleic Acids Res 35: 4359-4368.
17. Shen M, Mattox W, (2012) Activation and repression functions of an SR splicing regulator depend on exonic versus intronic-binding position. Nucleic Acids Res 40: 428-437.
18. Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, López-Picazo JM, et al. (2010) The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res 16: 4113-4125.
19. Mole S, McFarlane M, Chuen-Im T, Milligan SG, Millan D, et al. (2009) RNA splicing factors regulated by HPV16 during cervical tumour progression. J Pathol 219: 383-391.
20. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, et al. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14: 185-193.
21. Sun D, Novotny M, Bulek K, Liu C, Li X, et al. (2011) Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol 12: 853-860.
22. Tamura T, Yanai H, Savitsky D, Taniguchi T, (2008) The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26: 535-584.
23. Owens BM, Moore JW, Kaye PM, (2012) IRF7 regulates TLR2-mediated activation of splenic CD11c (hi) dendritic cells. PLoS One 7: e41050.
24. Li Q, Tainsky MA, (2011) Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS One 6: e28683.
25. tenOever BR, Servant MJ, Grandvaux N, Lin R, Hiscott J, (2002) Recognition of the measles virus nucleocapsid as a mechanism of IRF-3 activation. J Virol 76: 3659-3669.
26. Paladino P, Collins SE, Mossman KL, (2010) Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses. PLoS One 5: e10428.
27. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, et al. (1998) Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J 17: 1087-1095.
28. Navarro L, Mowen K, Rodems S, Weaver B, Reich N, et al. (1998) Cytomegalovirus activates interferon immediate-early response gene expression and an interferon regulatory factor 3-containing interferon-stimulated response element-binding complex. Mol Cell Biol 18: 3796-3802.
29. Lin R, Heylbroeck C, Genin P, Pitha PM, Hiscott J, (1999) Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription. Mol Cell Biol 19: 959-966.
30. Takaoka A, Yanai H, (2006) Interferon signalling network in innate defence. Cell Microbiol 8: 907-922.
31. Levy DE, Marié I, Prakash A, (2003) Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity. Curr Opin Immunol 15: 52-58.
32. Lin R, Mamane Y, Hiscott J, (1999) Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains. Mol Cell Biol 19: 2465-2474.
33. Lin R, Heylbroeck C, Pitha PM, Hiscott J, (1998) Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 18: 2986-2996.
34. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, et al. (2003) Triggering the interferon antiviral response through an IKK-related pathway. Science 300: 1148-1151.
35. Karpova AY, Howley PM, Ronco LV, (2000) Dual utilization of an acceptor/donor splice site governs the alternative splicing of the IRF-3 gene. Genes Dev 14: 2813-2818.
36. Karpova AY, Ronco LV, Howley PM, (2001) Functional characterization of interferon regulatory factor 3a (IRF-3a), an alternative splice isoform of IRF-3. Mol Cell Biol 21: 4169-4176.
37. Li Y, Hu X, Song Y, Lu Z, Ning T, et al. (2011) Identification of novel alternative splicing variants of interferon regulatory factor 3. Biochim Biophys Acta 1809: 166-175.
38. Somberg M, Schwartz S, (2010) Multiple ASF/SF2 sites in the human papillomavirus type 16 (HPV-16) E4-coding region promote splicing to the most commonly used 3'-splice site on the HPV-16 genome. J Virol 84: 8219-8230.
39. Burd CG, Dreyfuss G, (1994) RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J 13: 1197-1204.
40. Lee J, Lee HJ, Shin MK, Ryu WS, (2004) Versatile PCR-mediated insertion or deletion mutagenesis. Biotechniques 36: 398-400.
41. Sadik CD, Bachmann M, Pfeilschifter J, Mühl H, (2009) Activation of interferon regulatory factor-3 via toll-like receptor 3 and immunomodulatory functions detected in A549 lung epithelial cells exposed to misplaced U1-snRNA. Nucleic Acids Res 37: 5041-5056.
42. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M, (1989) Prolonged activation of JUN and collagenase genes by tumour necrosis factor-alpha. Nature 337: 661-663.
43. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M, (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244-247.
44. Qian BZ, Pollard JW, (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
45. Joyce JA, Pollard JW, (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
46. Tarassishin L, Suh HS, Lee SC, (2011) Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway. J Neuroinflammation 8: 187.
47. Kim TY, Lee KH, Chang S, Chung C, Lee HW, et al. (2003) Oncogenic potential of a dominant negative mutant of interferon regulatory factor 3. J Biol Chem 278: 15272-15278.
48. Duguay D, Mercier F, Stagg J, Martineau D, Bramson J, et al. (2002) In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res 62: 5148-5152.
49. Tokunaga T, Naruke Y, Shigematsu S, Kohno T, Yasui K, et al. (2010) Aberrant expression of interferon regulatory factor 3 in human lung cancer. Biochem Biophys Res Commun 397: 202-207.
50. Wang SS, Bratti MC, Rodríguez AC, Herrero R, Burk RD, et al. (2009) Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis 199: 20-30.
51. Slattery ML, Lundgreen A, Bondurant KL, Wolff RK, (2011) Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis 32: 1660-1667.
52. Grivennikov SI, Greten FR, Karin M, (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
53. Mantovani A, (2010) Molecular pathways linking inflammation and cancer. Curr Mol Med 10: 369-373.
54. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
55. Chew V, Chen J, Lee D, Loh E, Lee J, et al. (2012) Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 61: 427-438.
56. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC, (2010) Regulatory T cells in cancer. Adv Cancer Res 107: 57-117.
57. Ostrand-Rosenberg S, Sinha P, (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506.
58. Pan H, Luo C, Li R, Qiao A, Zhang L, et al. (2008) Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J Biol Chem 283: 623-637.
59. Altraja S, Jaama J, Valk E, Altraja A, (2009) Changes in the proteome of human bronchial epithelial cells following stimulation with leucotriene E4 and transforming growth factor-beta1. Respirology 14: 39-45.